Extramedullary relapses after allogeneic non-myeloablative stem cell transplantation in multiple myeloma patients do not negatively affect treatment outcome

ABSTRACT Recent literature suggests that after non-myeloablative allogeneic (NMA) stem cell transplantation (SCT), the incidence of extramedullary (EM) relapse in multiple myeloma (MM)

patients is increased and that these relapses have a poor prognosis. However, numbers on incidence and treatment outcome are scarce. We collected data from 54 relapsed MM patients from a

total group of 172 treated with sequential autologous and allogeneic NMA SCT at seven transplantation centres. There were 43 (79.6%) systemic relapses, including 6 with concurrent EM

localisation. Five patients had a local EM relapse only. Six patients relapsed with only bone involvement. Patients with deletion of chromosome 13 had a higher incidence of EM relapse (30.8

versus 5.6%, _P_=0.06). EM relapses were treated with donor lymphocyte infusion, radiotherapy, or chemotherapy, especially with novel agents. The response rate was 45.5%, which was not

different when compared to patients without EM disease (54.1%). Overall survival and progression-free survival were not significantly different in patients with EM disease, when compared to

those without EM disease. In conclusion, the incidence of relapse with EM disease following allogeneic NMA SCT was 20.4%. There was no negative impact of EM relapse on response rate, overall

survival and progression-free survival. Access through your institution Buy or subscribe This is a preview of subscription content, access via your institution ACCESS OPTIONS Access through

your institution Subscribe to this journal Receive 12 print issues and online access $259.00 per year only $21.58 per issue Learn more Buy this article * Purchase on SpringerLink * Instant

access to full article PDF Buy now Prices may be subject to local taxes which are calculated during checkout ADDITIONAL ACCESS OPTIONS: * Log in * Learn about institutional subscriptions *

Read our FAQs * Contact customer support SIMILAR CONTENT BEING VIEWED BY OTHERS EXTRA-MEDULLARY RECURRENCE OF MYELOID LEUKEMIA AS MYELOID SARCOMA AFTER ALLOGENEIC STEM CELL TRANSPLANTATION:

IMPACT OF CONDITIONING INTENSITY Article Open access 30 June 2020 CHARACTERISTICS AND OUTCOMES OF THERAPY-RELATED ACUTE LEUKEMIA FOLLOWING AUTOLOGOUS TRANSPLANT (AUTO-HCT) FOR MULTIPLE

MYELOMA Article Open access 30 October 2024 MULTIPLE MYELOMA PATIENTS WITH A LONG REMISSION AFTER AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION Article Open access 17 May 2024

REFERENCES * Maloney DG, Molina AJ, Sahebi F, Stockerl-Goldstein KE, Sandmaier BM, Bensinger W _et al_. Allografting with nonmyeloablative conditioning following cytoreductive autografts for

the treatment of patients with multiple myeloma. _Blood_ 2003; 102: 3447–3454. Article  CAS  PubMed  Google Scholar  * Lokhorst HM, Wu K, Verdonck LF, Laterveer LL, van de Donk NW, van Oers

MH _et al_. The occurrence of graft-versus-host disease is the major predictive factor for response to donor lymphocyte infusions in multiple myeloma. _Blood_ 2004; 103: 4362–4364. Article

  CAS  PubMed  Google Scholar  * Perez-Simon JA, Sureda A, Fernandez-Aviles F, Sampol A, Cabrera JR, Caballero D _et al_. Reduced-intensity conditioning allogeneic transplantation is

associated with a high incidence of extramedullary relapses in multiple myeloma patients. _Leukemia_ 2006; 20: 542–545. Article  CAS  PubMed  Google Scholar  * Byrne JL, Fairbairn J, Davy B,

Carter IG, Bessell EM, Russell NH . Allogeneic transplantation for multiple myeloma: late relapse may occur as localised lytic lesion/plasmacytoma despite ongoing molecular remission. _Bone

Marrow Transplant_ 2003; 31: 157–161. Article  CAS  PubMed  Google Scholar  * Terpos E, Rezvani K, Basu S, Milne AE, Rose PE, Scott GL _et al_. Plasmacytoma relapses in the absence of

systemic progression post-high-dose therapy for multiple myeloma. _Eur J Haematol_ 2005; 75: 376–383. Article  PubMed  Google Scholar  * Zeiser R, Deschler B, Bertz H, Finke J, Engelhardt M

. Extramedullary vs medullary relapse after autologous or allogeneic hematopoietic stem cell transplantation (HSCT) in multiple myeloma (MM) and its correlation to clinical outcome. _Bone

Marrow Transplant_ 2004; 34: 1057–1065. Article  CAS  PubMed  Google Scholar  * Patriarca F, Prosdocimo S, Tomadini V, Vasciaveo A, Bruno B, Fanin R . Efficacy of bortezomib therapy for

extramedullary relapse of myeloma after autologous and non-myeloablative allogeneic transplantation. _Haematologica_ 2005; 90: 278–279. PubMed  Google Scholar  * Biagi JJ, Mileshkin L, Grigg

AP, Westerman DW, Prince HM . Efficacy of thalidomide therapy for extramedullary relapse of myeloma following allogeneic transplantation. _Bone Marrow Transplant_ 2001; 28: 1145–1150.

Article  CAS  PubMed  Google Scholar  * Durie BG, Harousseau JL, Miguel JS, Blade J, Barlogie B, Anderson K _et al_. International uniform response criteria for multiple myeloma. _Leukemia_

2006; 20: 1467–1473. Article  CAS  PubMed  Google Scholar  * International Myeloma Working Group. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related

disorders: a report of the International Myeloma Working Group. _Br J Haematol_ 2003; 121: 749–757. Article  Google Scholar  * Glucksberg H, Storb R, Fefer A, Buckner CD, Neiman PE, Clift RA

_et al_. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. _Transplantation_ 1974; 18: 295–304. Article  CAS  PubMed 

Google Scholar  * Shulman HM, Sullivan KM, Weiden PL, McDonald GB, Striker GE, Sale GE _et al_. Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle

patients. _Am J Med_ 1980; 69: 204–217. Article  CAS  PubMed  Google Scholar  * Blade J, Samson D, Reece D, Apperley J, Bjorkstrand B, Gahrton G _et al_. Criteria for evaluating disease

response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood

and Marrow Transplant. _Br J Haematol_ 1998; 102: 1115–1123. Article  CAS  PubMed  Google Scholar  * Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM _et al_. Report of an

international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. _J Clin Oncol_ 1999; 17: 1244. Article  CAS  PubMed 

Google Scholar  * Chong G, Byrnes G, Szer J, Grigg A . Extramedullary relapse after allogeneic bone marrow transplantation for haematological malignancy. _Bone Marrow Transplant_ 2000; 26:

1011–1015. Article  CAS  PubMed  Google Scholar  * Lee KH, Lee JH, Choi SJ, Lee JH, Kim S, Seol M _et al_. Bone marrow vs extramedullary relapse of acute leukemia after allogeneic

hematopoietic cell transplantation: risk factors and clinical course. _Bone Marrow Transplant_ 2003; 32: 835–842. Article  CAS  PubMed  Google Scholar  * Fassas AB, Ward S, Muwalla F, Van

HR, Schluterman K, Harik S _et al_. Myeloma of the central nervous system: strong association with unfavorable chromosomal abnormalities and other high-risk disease features. _Leuk Lymphoma_

2004; 45: 291–300. Article  PubMed  Google Scholar  * van de Donk NW, Kroger N, Hegenbart U, Corradini P, San Miguel JF, Goldschmidt H _et al_. Remarkable activity of novel agents

bortezomib and thalidomide in patients not responding to donor lymphocyte infusions following nonmyeloablative allogeneic stem cell transplantation in multiple myeloma. _Blood_ 2006; 107:

3415–3416. Article  CAS  PubMed  Google Scholar  Download references AUTHOR INFORMATION AUTHORS AND AFFILIATIONS * Department of Hematology, University Medical Center Utrecht, Utrecht, The

Netherlands M C Minnema, N W C J van de Donk & H M Lokhorst * Department of Hematology, Free University Medical Center, Amsterdam, The Netherlands S Zweegman * Department of

Hematology/Oncology, Clinic of Internal Medicine, University of Heidelberg, Heidelberg, Germany U Hegenbart & S Schonland * Department of Hematology, University Medical Center Nijmegen,

St Radboud University, Nijmegen, The Netherlands R Raymakers * Department of Hematology, Erasmus MC, Rotterdam, The Netherlands J M J M Zijlmans * Department of Hematology, Academic Medical

Center, Amsterdam, The Netherlands M J Kersten * Department of Internal Medicine, Sub-division of Hematology, Academic Hospital Maastricht, Maastricht, The Netherlands G M J Bos Authors * M

C Minnema View author publications You can also search for this author inPubMed Google Scholar * N W C J van de Donk View author publications You can also search for this author inPubMed 

Google Scholar * S Zweegman View author publications You can also search for this author inPubMed Google Scholar * U Hegenbart View author publications You can also search for this author

inPubMed Google Scholar * S Schonland View author publications You can also search for this author inPubMed Google Scholar * R Raymakers View author publications You can also search for this

author inPubMed Google Scholar * J M J M Zijlmans View author publications You can also search for this author inPubMed Google Scholar * M J Kersten View author publications You can also

search for this author inPubMed Google Scholar * G M J Bos View author publications You can also search for this author inPubMed Google Scholar * H M Lokhorst View author publications You

can also search for this author inPubMed Google Scholar CORRESPONDING AUTHOR Correspondence to M C Minnema. RIGHTS AND PERMISSIONS Reprints and permissions ABOUT THIS ARTICLE CITE THIS

ARTICLE Minnema, M., van de Donk, N., Zweegman, S. _et al._ Extramedullary relapses after allogeneic non-myeloablative stem cell transplantation in multiple myeloma patients do not

negatively affect treatment outcome. _Bone Marrow Transplant_ 41, 779–784 (2008). https://doi.org/10.1038/sj.bmt.1705982 Download citation * Received: 22 May 2007 * Revised: 26 September

2007 * Accepted: 19 November 2007 * Published: 14 January 2008 * Issue Date: May 2008 * DOI: https://doi.org/10.1038/sj.bmt.1705982 SHARE THIS ARTICLE Anyone you share the following link

with will be able to read this content: Get shareable link Sorry, a shareable link is not currently available for this article. Copy to clipboard Provided by the Springer Nature SharedIt

content-sharing initiative KEYWORDS * multiple myeloma * non-myeloablative allogeneic stem cell transplantation * extramedullary relapse